Acute myeloid leukemia cost-effectiveness of therapy: Difference between revisions
No edit summary |
|||
| Line 3: | Line 3: | ||
{{Acute myeloid leukemia}} | {{Acute myeloid leukemia}} | ||
{{CMG}} {{shyam}} | {{CMG}}; {{AE}} {{shyam}}; {{GRR}} {{Nat}} | ||
==Overview== | ==Overview== | ||
Latest revision as of 13:07, 11 April 2019
|
Acute myeloid leukemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Acute myeloid leukemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute myeloid leukemia cost-effectiveness of therapy |
|
Acute myeloid leukemia cost-effectiveness of therapy in the news |
|
Blogs on Acute myeloid leukemia cost-effectiveness of therapy |
|
Risk calculators and risk factors for Acute myeloid leukemia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shyam Patel [2]; Grammar Reviewer: Natalie Harpenau, B.S.[3]
Overview
A limited number of cost-effective studies have been done. For the acute promyelocytic leukemia subtype of acute myeloid leukemia, these studies showed that all-trans retinoic acid-based therapy is more cost-effective than chemotherapy.
Cost-effectiveness of therapy
A limited number of cost-effectiveness studies have been performed in acute myeloid leukemia. One comprehensive cost-effective analysis studied the costs of therapy.
- The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
- The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.